• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Positive Phase 3 Deucrictibant Data in HAE Redefine Pharvaris' (PHVS) Orphan-Drug Narrative

    Simply Wall St·09/05/2026 23:23:24
    Listen to the news
    • Pharvaris recently reported data from oral and poster presentations at the Bradykinin Symposium 2026 in Berlin, highlighting in silico modeling, proteomic analyses, and Phase 3 clinical trial results for its oral bradykinin B2 receptor antagonist deucrictibant in hereditary angioedema.
    • An interesting takeaway is that long-term prophylaxis studies with oral deucrictibant indicated durable reductions in hereditary angioedema attack rates alongside sustained improvements in patients’ quality of life.
    • We will now examine how the positive Phase 3 efficacy and safety data for oral deucrictibant could shape Pharvaris’s investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    What Is Pharvaris' Investment Narrative?

    To own Pharvaris, you have to believe that deucrictibant can convert its clinical profile into a meaningful hereditary angioedema franchise before the cash burn and shareholder dilution bite too hard. The Bradykinin Symposium 2026 data slot neatly into that story, reinforcing the Phase 3 efficacy and safety narrative and, by extension, the near term regulatory catalysts around the already accepted NDA for on demand treatment and the coming CHAPTER 3 prophylaxis readout. In the short term, this package looks more confirmatory than transformational, but it may strengthen confidence in the dual on demand and prophylaxis strategy that underpins many growth assumptions. The flip side is clear: Pharvaris still has zero revenue, sizeable recurring losses and a history of raising equity to fund operations.

    However, investors should not overlook one specific risk that could reshape expectations. Despite retreating, Pharvaris' shares might still be trading above their fair value and there could be some more downside. Discover how much.

    Exploring Other Perspectives

    PHVS 1-Year Stock Price Chart
    PHVS 1-Year Stock Price Chart

    Two fair value views from the Simply Wall St Community range from US$49.26 to a very large US$455.66 per share, underlining how differently people are weighing deucrictibant’s Phase 3 data and regulatory timing. You are looking at a stock where enthusiasm around clinical success meets ongoing losses and funding needs, so it can pay to compare multiple viewpoints before forming your own stance.

    Explore 2 other fair value estimates on Pharvaris - why the stock might be worth just $49.26!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Interested In Other Possibilities?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.